港股上市公司三生制药（01530.HK）今日盘中大涨5.02%，引发市场关注。消息面上，公司近期发布的2024年财报显示业绩表现亮眼，且研发管线丰富，获得多家券商看好。
财报显示，三生制药2024年实现营收91.08亿元，同比增长16.53%；归母净利润为20.90亿元，同比增长34.93%。公司核心产品特比澳（重组人血小板生成素）2024年销售收入约为50.62亿元，同比增长20.4%，继续保持市场龙头地位。此外，公司在研产品管线丰富，目前拥有30项在研产品，覆盖血液/肿瘤、自身免疫及眼科等多个领域。
多家券商对三生制药给予积极评级。招银国际表示，三生制药凭借强大的商业产品组合和不断扩展的产品线，具备可持续长期增长的良好定位，将目标价上调至14.18港元，维持"买入"评级。花旗银行则将评级由"中性"上调至"买入"，目标价上调至13港元。分析师认为，公司业绩强劲，研发管线进展顺利，有望持续保持高增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.